The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | autoHSCT as the best predictor for long-term survival in multiple myeloma
Guillermo José Ruiz-Argüelles, MD, FRCP, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico, talks on the use of autologous hematopoietic stem cell transplantation (autoHSCT) to predict long-term survival in patients with multiple myeloma. A recent study conducted in Mexico demonstrated that autoHSCT was the best determinant of long-term survival irrespective of other characteristics of the disease. In addition, Prof. Ruiz-Argüelles explains that Latin American patients with multiple myeloma have a better prognosis than other populations. According to Prof. Ruiz-Argüelles, autoHSCT is the best available treatment for multiple myeloma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
